Poly(lactic-co-glycolic) Acid as a Slow-Release Drug-Carrying Matrix for Methotrexate Coated onto Intraocular Lenses to Conquer Posterior Capsule Opacification

References

• Kahraman G, Ferdinaro C, Wetzel B, Bernhart C, Prager F, Amon M. Intraindividual comparison of capsule behavior of 2 hydrophobic acrylic intraocular lenses during a 5-year follow-up. J Cataract Refract Surg. 2017;43(2):228–33. doi:10.1016/j.jcrs.2016.12.015.
   PubMed Web of Science ®Google Scholar
• Nibourg LM, Gelens E, Kuijer R, Hooymans JM, van Kooten TG, Koopmans SA. Prevention of posterior capsular opacification. Exp Eye Res. 2015;136:100–15. doi:10.1016/j.exer.2015.03.011.
   PubMed Web of Science ®Google Scholar
• Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377–97. doi:10.3390/polym3031377.
   PubMed Web of Science ®Google Scholar
• Wertheimer C, Siedlecki J, Kook D, Mayer WJ, Wolf A, Klingenstein A, Kampik A, Eibl-Lindner K. EGFR inhibitor Gefitinib attenuates posterior capsule opacification in vitro and in the ex vivo human capsular bag model. Graefes Arch Clin Exp Ophthalmol. 2015;253(3):409–17. doi:10.1007/s00417-014-2875-0.
   PubMed Web of Science ®Google Scholar
• Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21(23):2475–90. doi:10.1016/S0142-9612(00)00115-0.
   PubMed Web of Science ®Google Scholar
• Conn J Jr., Oyasu R, Welsh M, Beal JM. Vicryl (polyglactin 910) synthetic absorbable sutures. Am J Surg. 1974;128(1):19–23. doi:10.1016/0002-9610(74)90228-1.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM; Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915–23. doi:10.1097/IAE.0b013e318206d18c.
   PubMed Web of Science ®Google Scholar
• Nishi O, Nishi K, Morita T, Tada Y, Shirasawa E, Sakanishi K. Effect of intraocular sustained release of indomethacin on postoperative inflammation and posterior capsule opacification. J Cataract Refract Surg. 1996;22(Suppl 1):806–10. doi:10.1016/S0886-3350(96)80166-0.
   PubMed Web of Science ®Google Scholar
• Liu H, Wu L, Fu S, Hou Y, Liu P, Cui H, Liu J, Xing L, Zhang X. Polylactide-glycoli acid and rapamycin coating intraocular lens prevent posterior capsular opacification in rabbit eyes. Graefes Arch Clin Exp Ophthalmol. 2009;247(6):801–07. doi:10.1007/s00417-008-1007-0.
   PubMed Web of Science ®Google Scholar
• Liu CS, Wormstone IM, Duncan G, Marcantonio JM, Webb SF, Davies PD. A study of human lens cell growth in vitro. A model for posterior capsule opacification. Invest Ophthalmol Vis Sci, 1996;37(5):906–14.
   PubMed Web of Science ®Google Scholar
• Bednarz J, Teifel M, Friedl P, Engelmann K. Immortalization of human corneal endothelial cells using electroporation protocol optimized for human corneal endothelial and human retinal pigment epithelial cells. Acta Ophthalmol Scand. 2000;78(2):130–36. doi:10.1034/j.1600-0420.2000.078002130.x.
   PubMedGoogle Scholar
• Wormstone IM, Tamiya S, Eldred JA, Lazaridis K, Chantry A, Reddan JR, Anderson I, Duncan G. Characterisation of TGF-beta2 signalling and function in a human lens cell line. Exp Eye Res. 2004;78(3):705–14. doi:10.1016/j.exer.2003.08.006.
   PubMed Web of Science ®Google Scholar
• Gotoh N, Perdue NR, Matsushima H, Sage EH, Yan Q, Clark JI. An in vitro model of posterior capsular opacity: SPARC and TGF-beta2 minimize epithelial-to-mesenchymal transition in lens epithelium. Invest Ophthalmol Vis Sci. 2007;48(10):4679–87. doi:10.1167/iovs.07-0091.
   PubMed Web of Science ®Google Scholar
• Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988;48(17):4827–33.
   PubMed Web of Science ®Google Scholar
• Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol. 2007;245(12):1837–42. doi:10.1007/s00417-007-0568-7.
   PubMed Web of Science ®Google Scholar
• Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2(2):329–33. doi:10.1038/nprot.2007.30.
   PubMed Web of Science ®Google Scholar
• Wormstone IM, Collison DJ, Hansom SP, Duncan G. A focus on the human lens in vitro. Environ Toxicol Pharmacol. 2006;21(2):215–21. doi:10.1016/j.etap.2005.07.012.
   PubMed Web of Science ®Google Scholar
• Nabai L, Kilani RT, Aminuddin F, Li Y, Ghahary A. Methotrexate modulates the expression of MMP-1 and type 1 collagen in dermal fibroblast. Mol Cell Biochem. 2015;409(1–2):213–24. doi:10.1007/s11010-015-2526-8.
   PubMed Web of Science ®Google Scholar
• Chen H, Yan L, Wang J, Sun Y, Li X, Zhao S, Zhu G, Liang Y. Methotrexate prevents epidural fibrosis through endoplasmic reticulum stress signalling pathway. Eur J Pharmacol. 2017;796:131–38. doi:10.1016/j.ejphar.2016.12.032.
   PubMed Web of Science ®Google Scholar
• Hansen TJ, Tyndall R, Soll DB. Methotrexate-anticollagen conjugate inhibits in vitro lens cell outgrowth. Invest Ophthalmol Vis Sci, 1987;28(7):1206–09.
   PubMed Web of Science ®Google Scholar
• Sternberg K, Terwee T, Stachs O, Guthoff R, Lobler M, Schmitz KP. Drug-induced secondary cataract prevention: experimental ex vivo and in vivo results with disulfiram, methotrexate and actinomycin D. Ophthalmic Res. 2010;44(4):225–36. doi:10.1159/000316696.
   PubMed Web of Science ®Google Scholar
• Sadaka A, Sisk RA, Osher JM, Toygar O, Duncan MK, Riemann CD. Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol. 2016;10:1811–17. doi:10.2147/OPTH.S111893.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Movaseghi M, Ramezani A, Peyman GA. Pilot study of safety and effect of combined intravitreal bevacizumab and methotrexate for neovascular age-related macular degeneration. Eur J Ophthalmol. 2011;21(1):77–82. doi:10.5301/EJO.2010.5696.
   PubMed Web of Science ®Google Scholar
• Eibl-Lindner KH, Wertheimer C, Kampik A. Intraocular lens as a drug delivery device: state of the art and future perspective. Klin Monbl Augenheilkd, 2016;233(2):172–78.
   PubMed Web of Science ®Google Scholar
• Duarte AR, Simplicio AL, Vega-Gonzalez A, Subra-Paternault P, Coimbra P, Gil MH, de Sousa HC, Duarte CM. Impregnation of an intraocular lens for ophthalmic drug delivery. Curr Drug Deliv. 2008;5(2):102–07. doi:10.2174/156720108783954851.
   PubMedGoogle Scholar
• Eldred JA, Spalton DJ, Wormstone IM. An in vitro evaluation of the Anew Zephyr open-bag IOL in the prevention of posterior capsule opacification using a human capsular bag model. Invest Ophthalmol Vis Sci. 2014;55(11):7057–64. doi:10.1167/iovs.14-15302.
   PubMed Web of Science ®Google Scholar
• Eibl KH, Wertheimer C, Kernt M, Wolf A, Kook D, Haritoglou C, Kampik A. Alkylphosphocholines for intraocular lens coating. J Cataract Refract Surg. 2013;39(3):438–45. doi:10.1016/j.jcrs.2012.09.028.
   PubMed Web of Science ®Google Scholar
• Huang YC, Jou JR. Intravitreal injections of methotrexate in treatment of primary central nervous system lymphoma with intraocular involvement. Kaohsiung J Med Sci. 2016;32(12):638–39. doi:10.1016/j.kjms.2016.07.010.
   PubMed Web of Science ®Google Scholar
• Manna S, Banerjee RK, Augsburger JJ, Al-Rjoub MF, Correa ZM. Ultrasonographical assessment of implanted biodegradable device for long-term slow release of methotrexate into the vitreous. Exp Eye Res. 2016;148:30–32. doi:10.1016/j.exer.2016.05.014.
   PubMed Web of Science ®Google Scholar
• Julian K, Langner-Wegscheider BJ, Haas A, De Smet MD. Intravitreal methotrexate in the management of presumed tuberculous serpiginous-like choroiditis. Retina. 2013;33(9):1943–48. doi:10.1097/IAE.0b013e318285cdbe.
   PubMed Web of Science ®Google Scholar
• Hardten DR. The cornea in cataract and intraocular lens surgery. Curr Opin Ophthalmol. 1996;7(1):43–48. doi:10.1097/00055735-199602000-00009.
   PubMedGoogle Scholar
• Walker TD. Pharmacological attempts to reduce posterior capsule opacification after cataract surgery–a review. Clin Exp Ophthalmol. 2008;36(9):883–90. doi:10.1111/j.1442-9071.2009.01921.x.
   PubMed Web of Science ®Google Scholar
• Rosado-Adames N, Afshari NA. The changing fate of the corneal endothelium in cataract surgery. Curr Opin Ophthalmol. 2012;23(1):3–6. doi:10.1097/ICU.0b013e32834e4b5f.
   PubMed Web of Science ®Google Scholar
• Ghasemi Falavarjani K, Golabi S, Hadavandkhani A. Effect of intravitreal injection of methotrexate on human corneal endothelial cells. Cornea. 2016;35(2):217–19. doi:10.1097/ICO.0000000000000700.
   PubMed Web of Science ®Google Scholar